ESR1 and breast carcinoma: Different from other cancer types, relapse events in patients with estrogen receptor–positive (ER+) breast cancer do not decline with time (7), do not spike at the end of adjuvant ETs (8), nor are significantly influenced by the size of the tumor (9, 10).